Get started
Author

Marc Pondel

Observed names: M Pondel, Pondel, Marc
ORCID: 0009-0002-3688-2263
Observed ORCID: 0009-0002-3688-2263
OpenAlex ID: A5036923804
P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
2021 · Bruce Sands, Marc Pondel, et al. · The American Journal of Gastroenterology · 12
PDF
DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
2022 · A Armuzzi, R K Cross, et al. · Journal of Crohn s and Colitis · 10
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
2021 · Millie Long, Raymond Cross, et al. · The American Journal of Gastroenterology · 8
Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
2024 · Ivo Abraham, Matthias Calamia, et al. · Journal of Medical Economics · 7
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma
2024 · Karen MacDonald, Marc Pondel, et al. · Journal of Medical Economics · 7
PDF
DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
2022 · B Siegmund, J Axelrad, et al. · Journal of Crohn s and Colitis · 6
Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer
2024 · Ivo Abraham, Matthias Calamia, et al. · Journal of Medical Economics · 3
PDF
15: Long-term Cardiac Safety of Ozanimod in Phase 3 Clinical Program of Ulcerative Colitis and Relapsing Multiple Sclerosis
2022 · Millie D. Long, Raymond K. Cross, et al. · Gastroenterology · 3
P431 Early mucosal healing at week, 10 with ozanimod predicts clinical outcomes at week, 52: Post hoc analysis of the phase, 3 True North clinical trial
2022 · W Reinisch, J Axelrad, et al. · Journal of Crohn s and Colitis · 3
S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
2021 · Bruce E. Sands, Dianne Nguyen, et al. · The American Journal of Gastroenterology · 3
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer
2024 · Karen MacDonald, Marc Pondel, et al. · Journal of Medical Economics · 2
PDF
Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.
2024 · Ivo Abraham, Marc Pondel, et al. · Journal of Clinical Oncology
PDF
Cost-efficiency and expanded access modeling of toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
2024 · Karen MacDonald, Marc Pondel, et al. · Journal of Clinical Oncology
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study
2021 · David Hudesman, Millie Long, et al. · The American Journal of Gastroenterology
S867 Ozanimod for Moderate-to-Severe Ulcerative Colitis: Results From the North American Population During Induction and Maintenance in the Phase 3 True North Study
2021 · David Hudesman, Millie D. Long, et al. · The American Journal of Gastroenterology
Works count: 17
Citation count: 64
H-index: 6
I10-index: 2
Year
Topic
Type